Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEVANTE phase 2b trial of inhaled AZD8630 in uncontrolled asthma at risk of exacerbation
MOH_2024-11-24_013745Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azd8630 in asthma (4 arms), sponsored by AstraZeneca. Primary endpoint: Primary endpoints not reported. Started Nov 2024; status: active, not recruiting.
02
Drugs
azd8630
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2024-11-24_013745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-24_013745.